Abstract
Prior to clinical trials of new TB drugs or therapeutic vaccines, it is necessary to develop monitoring tools to predict treatment outcomes in TB patients. Urine interferon gamma inducible protein 10 (IP-10) is a potential biomarker of treatment response in chronic hepatitis C virus infection and lung diseases, including tuberculosis. In this study, we assessed IP-10 levels in urine samples from patients with active TB at diagnosis, during treatment, and at completion, and compared these with levels in serum samples collected in parallel from matched patients to determine whether urine IP-10 can be used to monitor treatment response in patients with active TB. IP-10 was measured using enzyme-linked immunosorbent assays in urine and serum samples collected concomitantly from 23 patients with active TB and 21 healthy adults (44 total individuals). The Mann-Whitney U test and Wilcoxon matched-pairs signed rank test were used for comparisons among healthy controls and patients at three time points, and LOESS regression was used for longitudinal data. The levels of IP-10 in urine increased significantly after 2 months of treatment (P = 0.0163), but decreased by the completion of treatment (P = 0.0035). Serum IP-10 levels exhibited a...Continue Reading
References
Sep 21, 2002·Lancet·Debra BenatorUNKNOWN Tuberculosis Trials Consortium
Feb 18, 2003·American Journal of Respiratory and Critical Care Medicine·Henry M BlumbergUNKNOWN American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society
Jun 19, 2007·Lancet·Haileyesus GetahunPaul Nunn
Feb 28, 2009·The Lancet Infectious Diseases·Robert S WallisAlimuddin Zumla
Feb 28, 2009·The Lancet Infectious Diseases·Michael J A Reid, N Sarita Shah
Jun 1, 2010·The Lancet Infectious Diseases·David J HorneKaren R Steingart
Oct 15, 2010·International Journal of Immunopathology and Pharmacology·E ProfumoR Riganò
Nov 26, 2010·BMC Infectious Diseases·Angela CannasDelia Goletti
May 21, 2011·BMC Infectious Diseases·Basirudeen Syed Ahamed KabeerDelia Goletti
May 19, 2012·PloS One·Catherine RiouGilla Kaplan
May 1, 2013·Nature Reviews. Drug Discovery·Alimuddin ZumlaStewart T Cole
Dec 5, 2014·Science Translational Medicine·M Teresa ColemanJoAnne L Flynn
Mar 19, 2015·Scientific Reports·Kristian TonbyAnne Ma Dyrhol-Riise
Oct 1, 2015·Workplace Health & Safety·Jennan A Phillips
Mar 13, 2016·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·Nils E Billo
Jun 12, 2016·BMC Infectious Diseases·James BrownMarc Lipman
Jul 7, 2016·Indian Journal of Clinical Biochemistry : IJCB·K RohiniA Mahesh Kumar
Jul 13, 2016·Infectious Disease Reports·Delia GolettiTom H M Ottenhoff
Sep 14, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Payam NahidAndrew Vernon
Oct 26, 2016·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·L PetroneD Goletti
Nov 1, 2017·Scientific Reports·Alberto L García-BasteiroRichard Anthony
Citations
Jul 21, 2020·PloS One·Olivia EstévezÁfrica González-Fernández
Apr 30, 2019·Expert Review of Proteomics·Deepa BishtVivek Kumar Gupta
Jul 3, 2021·Pathogens·Simona StefanescuCatalina-Gabriela Pisoschi